The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Telix Pharmaceuticals’ Illuccix gets US FDA label expansion to add patient selection for radioligand therapy: Melbourne, Australia Wednesday, June 25, 2025, 17:00 Hrs [IST] Melb ...

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 14, JonesTrading ...

JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane ...

Broker UBS believes the three-year rout of ASX healthcare stocks is near an end and it has promoted Cochlear and Resmed to ...

Common isotopes include lutetium-177, actinium-225, gallium-68 (diagnostic), fluorine-18, and radium-223. The therapy combines isotopic radiance with molecular targeting-e.g., PSMA in prostate cancer ...

FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix's first generation PSMA-PET imaging ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a Radiopharmaceutical Therapy Trials with Dosimetry session. Dr.

A misdiagnosis can change everything. When a healthcare provider fails to identify a condition correctly, it can lead to delayed treatment, unnecessary procedures, or the complete absence of care. For ...